ArticleDiscover nano2026
Green synthesized cobalt doped graphene quantum dots derived from Boswellia serrata for dual ligand targeted bioimaging and delivery of exemestane.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major objective of hydrothermal method is to achieve the synthesis of Cobalt doped Graphene quantum dots (Co-GQDs) using natural precursor (Boswellia serrata gum resin). The Co-GQDs were surface engineered with folic acid (FA) and hyaluronic acid (HA) to enable dual targeting module (Co-GQDFH), followed by loading of the anticancer drug Exemestane (EXE@Co-GQDs). The nanosized, crystallite structure with high luminescence intensity was maintained after functionalization and drug loading process was assessed from preliminary physicochemical analysis. The EXE@Co-GQDFH forms complex via passive loading approach and achieves and entrapment efficiency of 68.58%. The in-vitro drug release study shows extended release of EXE from the surface functionalized Co-GQDFH for 24 h and releases (~ 88%) maximum encapsulated drug. The dose dependent toxicity was observed for EXE@Co-GQDFH (49.5 µg/ml) on MCF-7 cell breast cancer cell types while IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.